STOCK TITAN

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences:

  • Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET
  • JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).

Deciphera Pharmaceuticals, Inc.

NASDAQ:DCPH

DCPH Rankings

DCPH Latest News

DCPH Stock Data

2.09B
41.33M
30.49%
73.45%
7.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About DCPH

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.